NantHealth (NASDAQ: NH) and Fluidigm (NASDAQ:FLDM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.
This is a summary of current ratings and price targets for NantHealth and Fluidigm, as reported by MarketBeat.
||Strong Buy Ratings
NantHealth presently has a consensus price target of $9.00, indicating a potential upside of 139.36%. Fluidigm has a consensus price target of $9.00, indicating a potential upside of 42.41%. Given NantHealth’s higher probable upside, research analysts clearly believe NantHealth is more favorable than Fluidigm.
Valuation & Earnings
This table compares NantHealth and Fluidigm’s gross revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Fluidigm has higher revenue and earnings than NantHealth. Fluidigm is trading at a lower price-to-earnings ratio than NantHealth, indicating that it is currently the more affordable of the two stocks.
This table compares NantHealth and Fluidigm’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Insider and Institutional Ownership
7.1% of NantHealth shares are owned by institutional investors. Comparatively, 93.3% of Fluidigm shares are owned by institutional investors. 58.0% of NantHealth shares are owned by insiders. Comparatively, 4.7% of Fluidigm shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
NantHealth beats Fluidigm on 7 of the 12 factors compared between the two stocks.
NantHealth Company Profile
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.
Fluidigm Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.